Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study to IDEntify Patients With Advanced/Metastatic NSCLC and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

NCT02679170 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02679170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02679170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study to IDEntify Patients With Advanced/Metastatic NSCLC and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
June 29, 2016
Completion date
May 4, 2022
Enrollment
692 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer